← All indications
Conjunctivitis, Allergic
Conjunctivitis due to hypersensitivity to various allergens.
Drugs by status
Approved for this indication (24)
- azelastine
- urea
- tobramycin
- cetirizine
- ketotifen
- cromoglicic acid
- cyproheptadine
- prednisone
- dexchlorpheniramine maleate
- epinastine
- hydrocortisone
- levocabastine
- nedocromil
- bepotastine
- loteprednol
- alcaftadine
- carbinoxamine maleate
- emedastine
- medrysone
- lodoxamide
- olopatadine
- promethazine hydrochloride
- antazoline
- dexamethasone
Phase 4 trials (19)
Phase 3 trials (18)
Phase 2 trials (18)
Phase 1 trials (5)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (30)
- Bausch Health Companies
- Alcon
- GlaxoSmithKline
- HAL Allergy
- Laboratoires Thea
- Menarini Group
- ORA, Inc.
- Samil Pharmaceutical Co., Ltd.
- Starx Research Center, LLC
- The Eye Center and The Eye Foundation for Research in Ophthalmology
- Hom, Milton M., OD, FAAO
- Aston University
- Harvard University
- Kyoto Prefectural University of Medicine
- Meiji University of Oriental Medicine
- Ophthalmic Consultants of Boston
- Southern California College of Optometry
- University of Iowa
- University of Padova
- University of Rochester
- Rush University
- Toyos Clinic
- Sun Yat-Sen University
- University of Montreal
- Minnesota Eye Consultants
- Shanghai Medical University
- Government of Belgium
- Ghent University
- University of Helsinki
- St. Justine's Hospital
Organization Involved with Phase 3 Indications (26)
- Aciex Therapeutics, Inc.
- Astellas
- Stallergenes
- Akorn, Inc.
- Aldeyra Therapeutics, Inc.
- Artu Biologicals
- Santen Inc.
- Faes Farma, S.A.
- Laboratorios Sophia S.A de C.V.
- Ocular Therapeutix, Inc.
- University of Roma La Sapienza
- Campus Bio-Medico University
- Siriraj Hospital
- Hebrew University
- AMPHA B.V.
- Centrum Immunologie a allergologie, Pavla Horova 14, 84108 Bratislava, Slovak Republic
- University of Genoa
- Technical University of Dresden
- PHT Corporation
- Aptuit Inc.
- Johnson and Johnson
- Eton Pharmaceuticals, Inc.
- LEH Pharma
- Sesen Bio
- IQVIA
- Marinomed Biotech AG
Organization Involved with Phase 2 Indications (36)
- Novelion Therapeutics
- Senju Pharmaceuticals
- Shire
- ASIT Biotech S.A.
- Allergopharma GmbH & Co. KG
- Anergis
- C.T. Development America, Inc.
- Eye Therapies, LLC
- Leti Pharma GmbH
- Mati Therapeutics Inc.
- Noveome Biotherapeutics
- Cytos Biotechnology AG
- National Polytechnic Institute, Mexico
- Koffler Vision Group
- University of Melbourne
- Vilnius University
- University of Valencia
- Tel Aviv University
- University of Cape Town
- Uppsala University
- Andover Eye Associates
- Inflamax
- Instituto Politécnico Nacional
- Karolinska Institute
- Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde
- Vanda Pharmaceuticals
- SPARC
- Sylvana Research Associates
- PRACS
- Allied Research International
- +6 more
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (4)